Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2154 Clinical and Morphological Features of Extrapulmonary Small-Cell Cancer

Introduction: Extrapulmonary Small-cell cancer (ESCC) is an extremely rare disease. Usually in the treatment of patients with ESCC approaches to the treatment of patients with small cell lung cancer (SCLC) are used.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Ivanov A, Gorbunova V, Delektorskaya V, Kuzminov A,

Keywords: small cell cancer, Extrapulmonary small cell cancer, somatostatin receptors,

#1338 Use of Lanreotide LAR in the Case of Intolerance of Octreotide LAR in Patients Well-differentiated NETs

Introduction: Intolerance of Octreotide is about 10 % of cases

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Gorbunova V, Orel N, Emelianova G, Kuzminov A, Markovich A,

Keywords: Octreotide, Lanreotide, intolerance, NETs,

#1275 Aranoza in the Treatment of Metastatic Neuroendocrine Tumors (NETs): Single Institution Experience

Introduction: Aranoza (3-α-L-arabinopyranosyl-1-methyl-nitrosourea) – nitrosourea derivative, as STZ.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Gorbunova V, Orel N, Kuzminov A, Emelianova G, Odintsova A,

Keywords: aranoza, Neuroendocrine tumors, chemotherapy,

#1091 IFNα versus IFNα Plus Octreotide LAR in Treatment of NETs

Introduction: It is still unknown whether the combination of IFNα with octreotide LAR has benefit compared with IFNα alone

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Gorbunova V, Emelianova G, Orel G, Markovich A, Kuzminov A,

Keywords: IFNα, Octreotide LAR, NETs,

#910 Experience of Temozolomide Mono- and Combination Therapy in Advanced Neuroendocrine Tumors (NETs) in Russia

Introduction: Temozolomide (T) demonstrated promising activity in NETs in numerous phase 2 studies worldwide. But there is not enough data about its efficacy in the Russian population.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Gorbunova V, Markovich A, Orel N, Kuzminov A, Odintsova A,

Keywords: temozolomide, neuroendocrine tumors ,